IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J. , March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation
March 25, 2024
IMUNON Files IND Application to Begin Human Testing of IMNN-101
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2 The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA   LAWRENCEVILLE, N.J. , March 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc .
March 13, 2024
IMUNON Announces Leadership Change
Executive Chairman to lead day-to-day operations, active search underway for CEO successor. Timing of upcoming milestones for key programs remains unchanged.  LAWRENCEVILLE, N.J. , March 12, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc . (NASDAQ: IMNN) , a clinical-stage drug-development company focused on
March 12, 2024